Hypothèses physiopathologiques dans les tumeurs épithéliales de l’ovaire

Fearon ER, Vogelstein B (1990) Genetic model for colorectal tumorigenesis. Cell 61: 759–67CrossRefPubMedGoogle Scholar

Resta L, Russo S, Colucci GA, Prat J (1993) Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 82: 208–18Google Scholar

Cheng PC, Gosewehr JA, Kim TM et al. (1996) Potential role of the inactivated X chromosome in ovarian epithelial tumor development. J Natl Cancer Inst 88: 510–8PubMedGoogle Scholar

Ford D, Easton DF, Stratton M et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676–89CrossRefPubMedGoogle Scholar

Russel SE, Hickey GI, Lowry WS et al. (1990) Allele loss from chromosome 17 in ovarian cancer. Oncogene 5:1581–3Google Scholar

Boyd J, Rubin SC (1997) Hereditary ovarian cancer: Molecular genetics and clinical implications. Gynecol Oncol 64:196–206CrossRefPubMedGoogle Scholar

Cliby W, Ritland S, Hartmann L et al. (1993) Human epithelial ovarian cancer allotype. Cancer Research 53(supp 10): 2393–8PubMedGoogle Scholar

Mazars R, Pujol P, Maudelonde T et al. (1991) p53 mutations in ovarian cancer: A late event? Oncogene 6: 1685–90PubMedGoogle Scholar

Pieretti M, Powell DE, Gallion HH et al. (1995) Genetic alterations on chromosome 17 distinguish different types of epithelial ovarian tumors. Hum Pathol 26: 393–7PubMedGoogle Scholar

Schultz DC, Vanderveer L, Buetow KH et al. (1995) Characterisation of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare al-terations involving 9p, including CDKN2. Cancer Res 55:2150–7PubMedGoogle Scholar

Yang DH, Smith ER, Cohen C et al. (2002) Cancer 94: 2380–92PubMedGoogle Scholar

Hellstrom I, Goodman G, Pullman J et al. (2001) Overexpression of HER2 in ovarian carcinomas. Cancer Research 61: 2420–3PubMedGoogle Scholar

Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (1997) A clinicopathologic and molecular study of 95 cases. Cancer 79: 1581–6CrossRefPubMedGoogle Scholar

Ortiz BH, Ailawadi M, Colitti C et al. (2001) Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Research 61: 7264–7PubMedGoogle Scholar

Bellacosa A, de Feo D, Godwin AK et al. (1995) Molecular alterations of the AKT2 oncogene in ovarian carcinomas. Int J Cancer 64: 280–5PubMedGoogle Scholar

Tashiro H, Miyazaki K, Okamura H et al. (1992) C-myc overexpression in human primary ovarian tumors: Its relevance to tumor progression. Int J Cancer 50: 828–33PubMedGoogle Scholar

Wright K, Wilson P, Morland S et al. (1999) Beta-catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16 % of endometrioid tumors. Int J Cancer 82: 625–9CrossRefPubMedGoogle Scholar

Ganesan S, Silver DP, Greenberg RA et al. (2002) BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 111: 393–405CrossRefPubMedGoogle Scholar

Spatz A, Borg C, Feuntun J (2004) X-chromosome genetics and human cancer. Nat Rev Cancer 4: 617–29CrossRefPubMedGoogle Scholar

Fathalla MF (1971) Incessant ovulation-a factor in ovarian neoplasia? Lancet 17: 163Google Scholar

Cramer DW Welch WR (1983) Determinants of ovarian cancer risk. Inferensis regarding pathogenesis. J Natl Cancer Inst. 71: 717–21PubMedGoogle Scholar

Orsulic S, Li Y, Soslow RA et al. (2002) Induction of ovarian cancer by defined multi-ple genetic changes in a mouse model system. Cancer cell 1: 53–62CrossRefPubMedGoogle Scholar

Dinulescu DM, Ince TA, Quade BJ et al. (2005) Nat Med 1: 63–70Google Scholar